1. The invention refers to a formula (LA) compound regulating the activity of adrenaline β - 3 receptor and its pharmacological components. 1. The compounds and their pharmacological components of the invention are useful methods for the treatment of moderate disorder of β - 3 adrenergic receptor, such as heart failure； heart performance of heart failure； mortality, recurrence rate and / or hospitalization rate related to heart failure； Keywords acute heart failure； acute heart failure； congestive heart failure； severe congestive heart failure；1. Dano in organs related to heart failure (such as Dano or renal failure, heart valve problems, heart rate problems and / or Dano hepatic)；Keywords heart failure caused by left ventricular dysfunction； heart failure caused by normal ejection； cardiovascular death caused by myocardial infarction； cardiovascular death in patients with left ventricular failure or left ventricular failure； left ventricular failure； a. Keywords left ventricular dysfunction； secondary heart failure, according to the New York Heart Association classification system；1. Grade 111 heart disease calculated according to the classification system of New York Heart Association；a. Grade 4 heart disease calculated according to the New York Heart Association classification system；LVEF lt； 40% X-ray colposcopy； LVEF lt； 35% X-ray or ventricular angiography； and related pathological conditions.La presente invencion se refiere a compuestos de la formula (la) y sus composiciones farmaceuticas que modulan la actividad del receptor beta-3 adrenergico. Los compuestos de la presente invencion y sus composiciones farmaceuticas se dirigen a metodos de utilidad en el tratamiento de un trastorno mediado por el receptor beta-3 adrenergico tales como insuficiencia cardiaca； rendimiento cardiaco en insuficiencia cardiaca； mortalidad, reinfarto, y/u hospitalizacion en relacion con insuficiencia cardiaca； insuficiencia cardiaca aguda； insuficiencia cardiaca descompensada ag
